Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 10/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 10/20 | 0.36 |
| ▸ | NNMT | P40261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3407162 | 1.00 | PTGS2 (0.42) | PTGS2MTNR1AMTNR1BNNMTKMT2A | |
| SCHEMBL3412295 | 0.88 | PTGS2 (0.44) | PTGS2MTNR1AMTNR1BNNMTKMT2A | |
| SCHEMBL3410325 | 0.87 | PTGS2 (0.43) | PTGS2MTNR1AMTNR1BNNMTKMT2A | |
| SCHEMBL3409609 | 0.81 | PTGS2 (0.39) | PTGS2MTNR1AMTNR1BNNMTKMT2A | |
| SCHEMBL3411112 | 0.78 | PTGS2 (0.46) | PTGS2MTNR1AMTNR1B | |
| SCHEMBL1840714 | 0.78 | PTGS2 (0.39) | PTGS2MTNR1AMTNR1BNNMTKMT2A | |
| SCHEMBL28794543 | 0.78 | PTGS2 (0.42) | PTGS2MTNR1AMTNR1B | |
| SCHEMBL1840716 | 0.76 | PTGS2 (0.40) | PTGS2MTNR1AMTNR1BHTR2C | |
| SCHEMBL3408951 | 0.76 | PTGS2 (0.40) | PTGS2MTNR1AMTNR1BHTR2C | |
| SCHEMBL3431599 | 0.76 | PTGS2 (0.43) | PTGS2MTNR1AMTNR1BHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2257551-B1 | AZATRICYCLIC ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-04-10 | — | — | EP | disclosed |
| US-8349828-B2 | Azatricyclic antibiotic compounds | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-01-08 | — | — | US | disclosed |
| US-20100331318-A1 | AZATRICYCLIC ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-12-30 | — | — | US | disclosed |
| EP-2257551-A2 | AZATRICYCLIC ANTIBIOTIC COMPOUNDS | Actelion Pharmaceuticals Ltd. (CH) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009104147-A2 | AZATRICYCLIC ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331318-A1 | AZATRICYCLIC ANTIBIOTIC COMPOUNDS | ZYX, AZI2, NAT1 | PTGS2 3245/4885MTNR1A 331/4885MTNR1B 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.